Regulation of Th2 responses by Lactococcus lactis subsp. cremoris YRC3780 alleviates DNCB-induced atopic dermatitis in the mouse model
oleh: Rong Wang, Haruyo Nakajima-Adachi, Yimei Wang, Yingyu Zhou, Wenting Gu, Erika Hiraide, Mamiko Morinaga, Ryogo Nakagawa, Shotaro Nakamura, Tomohiro Takano, Xuyang Li, Mayumi Saeki, Osamu Kaminuma, Takachika Hiroi, Kenji Uchida, Hidemasa Motoshima, Masaru Tanokura, Takuya Miyakawa, Satoshi Hachimura
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2022-07-01 |
Deskripsi
Lactococcus lactis subsp. cremoris YRC3780 (L. cremoris YRC3780) was isolated from kefir, and anti-allergic effects have been confirmed in humans. The mechanisms by which L. cremoris YRC3780 affects the Th1/Th2 balance in mice were investigated in vitro, focusing on the intestinal immune response. Simultaneously, a 2,4-dinitrochlorobenzene-induced atopic dermatitis mouse model was used to evaluate the symptom improvement effect of oral administration of L. cremoris YRC3780. The results showed that L. cremoris YRC3780 enhanced IFN-γ and IL-12 production and inhibited IL-4 production from CD4+ T cells in the presence of various types of immune cells. Oral administration of L. cremoris YRC3780 attenuated serum total IgE (p < 0.05) and decreased ear thickness (p < 0.05) in the atopic dermatitis model. The examination of cytokine expression suggested that L. cremoris YRC3780 improved AD-like symptoms by inhibiting IL-4 gene expression from Peyer's patches CD4+ T cells (p < 0.01) and IL-33 gene expression (p < 0.05) in the draining lymph nodes.